Cantor Warren J, Mahaffey Kenneth W, Huang Zhen, Das Pranab, Gulba Dietrich C, Glezer Stanislav, Gallo Richard, Ducas John, Cohen Marc, Antman Elliott M, Langer Anatoly, Kleiman Neal S, White Harvey D, Chisholm Robert J, Harrington Robert A, Ferguson James J, Califf Robert M, Goodman Shaun G
Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
Catheter Cardiovasc Interv. 2007 Jan;69(1):73-83. doi: 10.1002/ccd.20897.
Our objective was to analyze the impact of arterial access site, sheath size, timing of sheath removal, and use of access site closure devices on high-risk patients with acute coronary syndromes (ACS).
In the SYNERGY trial, 9,978 patients with ACS were randomly assigned to receive enoxaparin or unfractionated heparin.
This analysis includes 9,404 patients for whom sheath access information was obtained for the first PCI procedure or diagnostic catheterization. Comparisons of baseline, angiographic, and procedural characteristics were carried out according to access site and sheath size.
Overall, 9,404 (94%) patients underwent angiography at a median of 21 hr (25th and 75th percentiles: 5, 42) and 4,687 (50%) underwent PCI at a median of 23 hr (6,49) of enrollment. The access site was femoral for 94.9% of cases, radial for 4.4%, and brachial for 0.7%. Radial access was associated with fewer transfusions than femoral access (0.9% vs. 4.8%, P=0.007). For femoral access, the rates of noncoronary artery bypass grafting (CABG)-related TIMI major bleeding by sheath size was 1.5% for 4 or 5 French (Fr), 1.6% for 6 Fr, 3.3% for 7 Fr, and 3.8% for >or=8 Fr (P<0.0001). After adjustment for baseline characteristics, femoral access site, larger sheath size, and delayed sheath removal were independent predictors of need for transfusion.
Smaller sheaths, radial access, and timely sheath removal may mitigate the bleeding risk associated with potent antithrombotic/platelet therapy and early catheterization.
我们的目的是分析动脉穿刺部位、鞘管尺寸、鞘管拔除时机以及使用穿刺部位闭合装置对急性冠状动脉综合征(ACS)高危患者的影响。
在SYNERGY试验中,9978例ACS患者被随机分配接受依诺肝素或普通肝素治疗。
该分析纳入了9404例在首次经皮冠状动脉介入治疗(PCI)手术或诊断性心导管检查时获得鞘管穿刺信息的患者。根据穿刺部位和鞘管尺寸对基线、血管造影和手术特征进行了比较。
总体而言,9404例(94%)患者在入组后中位21小时(第25和第75百分位数:5、42)接受了血管造影,4687例(50%)患者在入组后中位23小时(6、49)接受了PCI。94.9%的病例穿刺部位为股动脉,4.4%为桡动脉,0.7%为肱动脉。桡动脉穿刺与输血次数少于股动脉穿刺相关(0.9%对4.8%,P = 0.007)。对于股动脉穿刺,按鞘管尺寸划分的非冠状动脉旁路移植术(CABG)相关的TIMI大出血发生率在4或5法国(Fr)为1.5%,6 Fr为1.6%,7 Fr为3.3%,≥8 Fr为3.8%(P<0.0001)。在对基线特征进行调整后,股动脉穿刺部位、较大的鞘管尺寸和延迟拔除鞘管是输血需求的独立预测因素。
较小的鞘管、桡动脉穿刺和及时拔除鞘管可能减轻与强效抗血栓/血小板治疗及早期心导管检查相关的出血风险。